Announcements Trials
Browse Landscape

Phase

Phase NA 3

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1CNS 1

Conditions

Breast Neoplasms 387Neoplasms 333Prostatic Neoplasms 188Lung Neoplasms 175Colorectal Neoplasms 142Motor Activity 87Pancreatic Neoplasms 73Uterine Cervical Neoplasms 70Brain Neoplasms 69Head and Neck Neoplasms 67Carcinoma, Non-Small-Cell Lung 63Ovarian Neoplasms 59Rectal Neoplasms 49Carcinoma, Hepatocellular 49Colonic Neoplasms 46Glioblastoma 42Anxiety Disorders 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Depression 39Neoplasm Metastasis 38Hematologic Neoplasms 37Melanoma 34Glioma 34Multiple Myeloma 33Disease 33Stomach Neoplasms 32Sarcoma 31Carcinoma, Renal Cell 30Urinary Bladder Neoplasms 29Pain 28

Interventions

Sufentanil 1Electroacupuncture 1((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase NA × Postoperative Nausea and Vomiting × 90 days × Clear all
NCT07479446 2026-05-22

Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery

Xuanwu Hospital, Beijing

Phase NA Recruiting
174 enrolled
CNS

Neuroma, Acoustic, Postoperative Nausea and Vomiting

NCT07515027 2026-04-13

Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery

Shanghai Chest Hospital

Phase NA Recruiting
204 enrolled

Postoperative Nausea and Vomiting

NCT07480785 2026-03-18

TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients

Zhejiang University

Phase NA Recruiting
780 enrolled
Gynecologic

Leiomyoma, Ovarian Neoplasms, Postoperative Nausea and Vomiting, Gallstones

Data powered by HemOnc (CC BY 4.0) Colophon âš¡